Skip to main content
SpringerLink
Log in

The significance of imaging examinations during follow-up for malignant melanoma

  • Clinical Report
  • Published:
European Journal of Dermatology Aims and scope

Abstract

Background

Currently, there is a general lack of consensus regarding optimal strategy and imaging during follow-up for patients suffering from melanoma.

Objectives

Our aim was to analyse the utility of various imaging procedures, in particular CT scans, during the follow-up of patients with different stages of melanoma.

Materials & Methods

A retrospective analysis of the medical records of patients suffering from melanoma diagnosed between 2001 and 2011 was carried out at the Department of Dermatology, University of Pécs. Patients with in situ (Stage 0) and metastatic (Stage IV) melanoma were excluded from the analysis, as well as patients who succumbed during the first three years of follow-up.

Results

In total, 649 melanoma patients met the inclusion criteria. During the entire follow-up period, 90 recurrences were detected. The vast majority (n = 71; 79%) of the total metastatic cases (n = 90) were diagnosed within the first three years. In 35% of the cases, metastases were detected by CT. Although more than 66% of the CT scans were performed for Stage I patients, only three cases were positive (0.1%) within this population.

Conclusion

On the basis of our results, intensive radiological work-up is not deemed necessary during the surveillance of patients in the early stages (IA–IIA) of melanoma. Initial and regular follow-up imaging examinations (preferably CT scans) may be recommended from Stage IIB of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. Ultraviolet radiation and the INTER-SUN Programme. (accessed 11 Dec 2016).

  2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199–206.

    Article  Google Scholar 

  3. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am 2011; 20: 1–17.

    Article  Google Scholar 

  4. Howlader N, Noone AM, Krapcho M, et al. Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, 1975–2014. National Cancer Institute. Bethesda, MD. Available at: https://seer.cancer.gov/archive/csr/1975_2014/ (accessed 2 Apr 2018).

    Google Scholar 

  5. Mrazek AA, Chao C. Surviving Cutaneous Melanoma: A Clinical Review of Follow-up Practices, Surveillance, and Management of Recurrence. Surg Clin North Am 2014; 94: 989–1002.

    Article  Google Scholar 

  6. Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol 2013; 6: 18–26.

    PubMed  PubMed Central  Google Scholar 

  7. Francken AB, Hoekstra HJ. Follow-Up of Melanoma Patients: The Need for Evidence-Based Protocols. Ann Surg Oncol 2009; 16: 804–5.

    Article  Google Scholar 

  8. Garbe C, Paul A, Kohler-Späth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21: 520–9.

    Article  Google Scholar 

  9. De Angelis R, Sant M, Coleman MP, et al. EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014; 15: 23–34.

    Article  Google Scholar 

  10. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471–4.

    Article  Google Scholar 

  11. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous Melanoma: ESMO Clinical Practice Guidelines. Ann Oncol 2015; 26: 126–32.

    Article  Google Scholar 

  12. Podlipnik S, Carrera C, Sanchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. J Am Acad Dermatol 2016; 75: 516–24.

    Article  Google Scholar 

  13. Davis SD. CT evaluation for pulmonary metastases in patients with extrathoracic malignancy. Radiology 1991; 180: 1–12.

    Article  CAS  Google Scholar 

  14. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: 99–105.

    Article  CAS  Google Scholar 

  15. Diederich S, Das M. Solitary pulmonary nodule: detection and management. Cancer Imaging 2006; 6: S42–6.

    Article  CAS  Google Scholar 

  16. Salama AK, de Rosa N, Scheri RP, et al. Hazard-Rate Analysis and Patterns of Recurrence in Early Stage Melanoma: Moving towards a Rationally Designed Surveillance Strategy. PLoS One 2013; 8: e57665.

    Article  CAS  Google Scholar 

  17. Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 2008; 95: 1401–7.

    Article  CAS  Google Scholar 

  18. Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe-a systematic review of the literature. Clin Epidemiol 2016; 8: 109–22.

    Article  Google Scholar 

  19. Gershenwald JE, Scolye RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol 2018; 8: 2105–10.

    Article  Google Scholar 

  20. Berman C, Reintgen D. Radiologic imaging in malignant melanoma: a review. Semin Surg Oncol 1993; 9: 232–8.

    CAS  PubMed  Google Scholar 

  21. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011; 103: 129–42.

    Article  Google Scholar 

  22. Gellén E, Sántha O, Janka E, et al. Diagnostic accuracy of (18) F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma. J Eur Acad Dermatol Venereol 2015; 29: 1938–44.

    Article  Google Scholar 

  23. Park TS, Phan GQ, Yang JC, et al. Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Ann Surg Oncol 2017; 24: 947–51.

    Article  Google Scholar 

  24. Leiter U, Marghoob AA, Lasithiotakis K, et al. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Res 2009; 19: 50–7.

    Article  Google Scholar 

  25. Pope WB. Brain metastases: neuroimaging. Handb Clin Neurol 2018; 149: 89–112.

    Article  Google Scholar 

  26. Deike-Hofmann K, Thünemann D, Breckwoldt MO, et al. Sensitivity of different MRI sequences in the early detection of melanoma brain metastases. PLoS One 2018; 13: e0193946.

    Article  Google Scholar 

  27. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumors: A retrospective cohort study. Lancet 2012; 380: 499–505.

    Article  Google Scholar 

  28. Berrington de Gonzalez A, Mahesh M, et al. Projected cancer risks from computed tomography scans performed in the United States in 2007. Arch Intern Med 2009; 169: 2071–7.

    Article  Google Scholar 

  29. Brenner DJ, Hall EJ. Computed tomography: an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277–84.

    Article  CAS  Google Scholar 

  30. Wen JC, Sai V, Straatsma BR, McCannel TA. Radiation-related cancer risk associated with surveillance imaging for metastatis from choroideal melanoma. JAMA Ophthalmol 2013; 131: 56–61.

    Article  Google Scholar 

  31. Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14: 1924–33.

    Article  Google Scholar 

  32. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6: 608–21.

    Article  Google Scholar 

  33. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O’Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274: 1703–5.

    Article  CAS  Google Scholar 

  34. National Comprehensive Cancer Network Inc. NCCN Clinical Practice Guidelines in oncology. Available at: www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (accessed 19 Dec 2019).

  35. Damude S, Hoekstra-Weebers JE, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year. Ann Surg Oncol 2016; 23: 2762–71.

    Article  Google Scholar 

  36. Nakamura Y, Kitano S, Takahashi A, et al. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 2016; 7: 77404–15.

    Article  Google Scholar 

Download references

Acknowledgements and disclosures

Acknowledgements: We wish to thank Dr. Zita Battyáni, MD, PhD for the conscientious work in the surveillance of melanoma patients, as well as the medical assistants (Ms. Andrea Kiss, Ms. Beatrix Gyurita and Ms. Bernadett Csizmadia) for organizing the examinations. Funding/support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Conflicts of interest: none. IRB Approval status: The study received approval from the Regional and Institutional Research Ethics Committee of the Medical School, Clinical Center, University of Pécs (IRB number: AOK/2018/7356).

Author information

Authors and Affiliations

  1. Department of Dermatology, Venerology and Oncodermatology, Medical School, Clinical Center, University of Pécs, 1. Akac Street, P.O.B.: H-7632, Pécs, Hungary

    Melánia Pozsgai, Klára Németh, Péter Oláh, Rolland Gyulai & Zsuzsanna Lengyel

Authors
  1. Melánia Pozsgai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Klára Németh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Péter Oláh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rolland Gyulai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zsuzsanna Lengyel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zsuzsanna Lengyel.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pozsgai, M., Németh, K., Oláh, P. et al. The significance of imaging examinations during follow-up for malignant melanoma. Eur J Dermatol 31, 357–363 (2021). https://doi.org/10.1684/ejd.2021.4054

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2021.4054

Key words

Search

Navigation